FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4223914656> ?p ?o ?g. }

• W4223914656 endingPage "2117" @default.
• W4223914656 startingPage "2109" @default.
• W4223914656 abstract "Abstract It is not clear whether pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum‐based chemotherapy (COMB) should be selected for patients with advanced non–small‐cell lung cancer (NSCLC) exhibiting high PD‐L1 expression (tumor proportion score ≥ 50%). We performed a retrospective, multicenter study of 300 patients with NSCLC exhibiting high PD‐L1 expression who received MONO or COMB as first‐line treatment between December 2018 and January 2020. We reviewed the medical records of all consecutive patients with no driver mutations, and assessed the patient characteristics, therapeutic regimens, treatment periods, and adverse events. In total, 166 (55%; median age: 74 years) and 134 (45%; median age: 68 years) patients received MONO and COMB, respectively. Patients were younger and had better performance status (0–1) in the COMB group ( p < 0.01). With a median follow‐up time of 10.6 (range: 0.1–20.6) months, the median progression‐free survival was 7.1 months with MONO and 13.1 months with COMB. The objective response rate was 42.2% with MONO and 67.9% with COMB. With respect to treatment discontinuation, 36 out of 166 (21.7%) and 28 out of 134 (20.1%) patients discontinued MONO and COMB, respectively. In conclusion, COMB may be a promising option for first‐line treatment for NSCLC with high PD‐L1 expression and good performance status." @default.
• W4223914656 created "2022-04-19" @default.
• W4223914656 creator A5003205817 @default.
• W4223914656 creator A5005018711 @default.
• W4223914656 creator A5014559854 @default.
• W4223914656 creator A5015201626 @default.
• W4223914656 creator A5015850178 @default.
• W4223914656 creator A5017789799 @default.
• W4223914656 creator A5028588267 @default.
• W4223914656 creator A5030272462 @default.
• W4223914656 creator A5033961075 @default.
• W4223914656 creator A5033975323 @default.
• W4223914656 creator A5034463390 @default.
• W4223914656 creator A5042218973 @default.
• W4223914656 creator A5044579640 @default.
• W4223914656 creator A5048574255 @default.
• W4223914656 creator A5052172218 @default.
• W4223914656 creator A5056890116 @default.
• W4223914656 creator A5071931123 @default.
• W4223914656 creator A5076423080 @default.
• W4223914656 creator A5076607777 @default.
• W4223914656 creator A5081639237 @default.
• W4223914656 date "2022-04-15" @default.
• W4223914656 modified "2023-10-16" @default.
• W4223914656 title "Current status of first‐line treatment with pembrolizumab for non–small‐cell lung cancer with high PD‐L1 expression" @default.
• W4223914656 cites W2019607817 @default.
• W4223914656 cites W2121960517 @default.
• W4223914656 cites W2527905628 @default.
• W4223914656 cites W2591717879 @default.
• W4223914656 cites W2925446385 @default.
• W4223914656 cites W2969539132 @default.
• W4223914656 cites W2987628800 @default.
• W4223914656 cites W2990357315 @default.
• W4223914656 cites W3004807713 @default.
• W4223914656 cites W3009099064 @default.
• W4223914656 cites W3015859409 @default.
• W4223914656 cites W3037506839 @default.
• W4223914656 cites W3044171569 @default.
• W4223914656 cites W3083679990 @default.
• W4223914656 cites W4223914656 @default.
• W4223914656 doi "https://doi.org/10.1111/cas.15361" @default.
• W4223914656 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35377496" @default.
• W4223914656 hasPublicationYear "2022" @default.
• W4223914656 type Work @default.
• W4223914656 citedByCount "1" @default.
• W4223914656 countsByYear W42239146562022 @default.
• W4223914656 crossrefType "journal-article" @default.
• W4223914656 hasAuthorship W4223914656A5003205817 @default.
• W4223914656 hasAuthorship W4223914656A5005018711 @default.
• W4223914656 hasAuthorship W4223914656A5014559854 @default.
• W4223914656 hasAuthorship W4223914656A5015201626 @default.
• W4223914656 hasAuthorship W4223914656A5015850178 @default.
• W4223914656 hasAuthorship W4223914656A5017789799 @default.
• W4223914656 hasAuthorship W4223914656A5028588267 @default.
• W4223914656 hasAuthorship W4223914656A5030272462 @default.
• W4223914656 hasAuthorship W4223914656A5033961075 @default.
• W4223914656 hasAuthorship W4223914656A5033975323 @default.
• W4223914656 hasAuthorship W4223914656A5034463390 @default.
• W4223914656 hasAuthorship W4223914656A5042218973 @default.
• W4223914656 hasAuthorship W4223914656A5044579640 @default.
• W4223914656 hasAuthorship W4223914656A5048574255 @default.
• W4223914656 hasAuthorship W4223914656A5052172218 @default.
• W4223914656 hasAuthorship W4223914656A5056890116 @default.
• W4223914656 hasAuthorship W4223914656A5071931123 @default.
• W4223914656 hasAuthorship W4223914656A5076423080 @default.
• W4223914656 hasAuthorship W4223914656A5076607777 @default.
• W4223914656 hasAuthorship W4223914656A5081639237 @default.
• W4223914656 hasBestOaLocation W42239146562 @default.
• W4223914656 hasConcept C121608353 @default.
• W4223914656 hasConcept C126322002 @default.
• W4223914656 hasConcept C143998085 @default.
• W4223914656 hasConcept C167135981 @default.
• W4223914656 hasConcept C197934379 @default.
• W4223914656 hasConcept C2776256026 @default.
• W4223914656 hasConcept C2776694085 @default.
• W4223914656 hasConcept C2776907518 @default.
• W4223914656 hasConcept C2777701055 @default.
• W4223914656 hasConcept C2778715236 @default.
• W4223914656 hasConcept C2780057760 @default.
• W4223914656 hasConcept C71924100 @default.
• W4223914656 hasConcept C90924648 @default.
• W4223914656 hasConceptScore W4223914656C121608353 @default.
• W4223914656 hasConceptScore W4223914656C126322002 @default.
• W4223914656 hasConceptScore W4223914656C143998085 @default.
• W4223914656 hasConceptScore W4223914656C167135981 @default.
• W4223914656 hasConceptScore W4223914656C197934379 @default.
• W4223914656 hasConceptScore W4223914656C2776256026 @default.
• W4223914656 hasConceptScore W4223914656C2776694085 @default.
• W4223914656 hasConceptScore W4223914656C2776907518 @default.
• W4223914656 hasConceptScore W4223914656C2777701055 @default.
• W4223914656 hasConceptScore W4223914656C2778715236 @default.
• W4223914656 hasConceptScore W4223914656C2780057760 @default.
• W4223914656 hasConceptScore W4223914656C71924100 @default.
• W4223914656 hasConceptScore W4223914656C90924648 @default.
• W4223914656 hasIssue "6" @default.
• W4223914656 hasLocation W42239146561 @default.
• W4223914656 hasLocation W42239146562 @default.
• W4223914656 hasLocation W42239146563 @default.

• next